Ariad Pharmaceuticals (ARIA): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Ariad Pharmaceuticals ( ARIA) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.7%. By the end of trading, Ariad Pharmaceuticals fell $0.10 (-1.5%) to $6.72 on light volume. Throughout the day, 14,589,199 shares of Ariad Pharmaceuticals exchanged hands as compared to its average daily volume of 28,464,600 shares. The stock ranged in price between $6.64-$6.98 after having opened the day at $6.94 as compared to the previous trading day's close of $6.82. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 23.6%, TetraLogic Pharmaceuticals Corporation ( TLOG), down 6.4%, CytRx Corporation ( CYTR), down 5.3% and Apricus Biosciences ( APRI), down 5.2%.

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. Ariad Pharmaceuticals has a market cap of $1.3 billion and is part of the health care sector. Shares are unchanged year to date as of the close of trading on Monday. Currently there are 3 analysts that rate Ariad Pharmaceuticals a buy, 3 analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Ariad Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself.

On the positive front, Neurocrine Biosciences ( NBIX), up 89.7%, Epizyme ( EPZM), up 75.6%, Pharmacyclics ( PCYC), up 19.8% and Imprimis Pharmaceuticals ( IMMY), up 19.2% , were all gainers within the drugs industry with Johnson & Johnson ( JNJ) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Short Seller Chanos Slams Tesla's Musk, Accuses Him of 'Incinerating' Capital

Short Seller Chanos Slams Tesla's Musk, Accuses Him of 'Incinerating' Capital

Stocks Rise, Nasdaq Jumps as Facebook Rallies

Stocks Rise, Nasdaq Jumps as Facebook Rallies

AMD Shares Explode After Solid Q1, Robust Outlook That Defies Chip Sector Gloom

AMD Shares Explode After Solid Q1, Robust Outlook That Defies Chip Sector Gloom

Facebook Stock Set for Biggest Gain in Two Years After Q1 Earnings Top Forecasts

Facebook Stock Set for Biggest Gain in Two Years After Q1 Earnings Top Forecasts

Earnings, Earnings and More Earnings - Your Midweek Update From Facebook to Ford

Earnings, Earnings and More Earnings - Your Midweek Update From Facebook to Ford